Decompression therapy helps restore spinal alignment by creating space between vertebrae, reducing nerve impingement, and enhancing overall spinal mobility and function
The prevalence varies between different drugs in the class, but these symptoms are generally reported as common

IR can disrupt this NAD + metabolism, diminishing sirtuin activity and weakening mitochondrial function and neuronal cell survival (Figure 1) ( FIGURE 1 6 GLP-1 and incretin mimetics in PD The incretin hormones known as GLP-1 and GIP are released from enteroendocrine L-cells and K-cells in the small intestine in response to nutrient ingestion, where they play a key role in regulating glucose metabolism and maintaining systemic nutrient homeostasis ( (Heloderma suspectum) saliva as a stable GLP-1 mimetic enabled appetite suppression and glycemic control in metabolic disease, driving the development of long-acting GLP-1 analogues and unimolecular agents that co-activate GLP-1 and GIP receptors ( Although direct involvement of GLP-1/GIP system abnormalities in PD remains uncertain, growing evidence shows that incretin-based therapies can improve cognitive function and exert neuroprotective effects, positioning them as promising candidates for treating neurodegenerative disorders ( In PD models, Agonists of GLP-1 receptor have also been shown to restore impaired GLUT expression and stabilize glucose uptake in brain that supports improvement in metabolic flexibility ( GLP-1 receptor agonists (e.g., exenatide, liraglutide, lixisenatide) and dual GLP-1/GIP agonists (e.g., tirzepatide) have been also reported to reduce microglial and astrocytic hyperactivation and suppress the release of inflammatory mediators such as TNF-, IL-1, and NF-B

We emphasize emerging insights into Treg dysfunction and discuss how these mechanisms are informing the development of targeted therapeutic interventions